Predictive Oncology Past Earnings Performance

Past criteria checks 0/6

Predictive Oncology has been growing earnings at an average annual rate of 5.7%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 5.9% per year.

Key information

5.7%

Earnings growth rate

69.7%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate5.9%
Return on equity-697.4%
Net Margin-924.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Predictive Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

MUN:S1K Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-14140
30 Jun 242-14150
31 Mar 242-15160
31 Dec 232-14150
30 Sep 232-17150
30 Jun 232-19170
31 Mar 231-26160
31 Dec 222-26160
30 Sep 222-26160
30 Jun 221-27150
31 Mar 221-19140
31 Dec 211-20140
30 Sep 211-23130
30 Jun 211-25130
31 Mar 211-26140
31 Dec 201-26130
30 Sep 201-29130
30 Jun 201-26140
31 Mar 201-21150
31 Dec 191-20140
30 Sep 191-9150
30 Jun 191-8130
31 Mar 191-1290
31 Dec 181-1090
30 Sep 181-870
30 Jun 181-660
31 Mar 181-670
31 Dec 171-670
30 Sep 171-660
30 Jun 171-660
31 Mar 171-650
31 Dec 160-760
30 Sep 161-870
30 Jun 160-870
31 Mar 161-770
31 Dec 151-550
30 Sep 151-550
30 Jun 151-550
31 Mar 151-560
31 Dec 141-770
30 Sep 141-770
30 Jun 141-990
31 Mar 140-990
31 Dec 130-990

Quality Earnings: S1K is currently unprofitable.

Growing Profit Margin: S1K is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: S1K is unprofitable, but has reduced losses over the past 5 years at a rate of 5.7% per year.

Accelerating Growth: Unable to compare S1K's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: S1K is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: S1K has a negative Return on Equity (-697.41%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 18:56
End of Day Share Price 2024/10/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Predictive Oncology Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
Vernon BernardinoH.C. Wainwright & Co.